Literature DB >> 25261210

What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.

Rebecca Schennach1, Michael Riedel, Michael Obermeier, Ilja Spellmann, Richard Musil, Markus Jäger, Max Schmauss, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G Schmidt, Wolfgang Gaebel, Joachim Klosterkötter, Isabella Heuser, Wolfgang Maier, Matthias R Lemke, Eckart Rüther, Stefan Klingberg, Markus Gastpar, Hans-Jürgen Möller.   

Abstract

The aim of this study was to evaluate residual symptoms in patients achieving remission according to the consensus criteria and to analyze their potential influence on the patient's outcome one year after discharge. In total, 399 patients suffering from a schizophrenia spectrum disorder were evaluated within a naturalistic study. Remission status was examined using the consensus criteria. Residual symptoms were defined as any symptom present at the time-point of remission following analogous analyses performed in depressed patients. Therefore, a PANSS item with a symptom severity of >1 (= at least borderline mentally ill) was defined to be a residual symptom. Remitters with and without residual symptoms were compared regarding psychopathology, functioning and side effects. In total, 236 patients (59%) were remitters at discharge with 94% of them suffering from at least one residual symptom. The most common residual symptoms were blunted affect (49%), conceptual disorganization (42%) and social withdrawal (40%). A significant association was found between the presence of residual symptoms and the severity of side effects (p < 0.0001) and functioning (p = 0.0003) at discharge as well as between residual symptoms and the risk of relapse and chance of remission one year after discharge. Residual symptoms were highly prevalent in remitted schizophrenia inpatients following the suggested definition. Most residual symptoms were persistent baseline symptoms suggesting an ongoing illness severity. Also, the necessity to re-evaluate the consensus criteria questioning the status of remission in these patients is also pointed out.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25261210     DOI: 10.1007/s00406-014-0528-2

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  37 in total

1.  A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials.

Authors:  R Schennach-Wolff; H-J Möller; M Jäger; F Seemüller; M Obermeier; T Messer; G Laux; H Pfeiffer; D Naber; L G Schmidt; W Gaebel; J Klosterkötter; I Heuser; W Maier; M R Lemke; E Rüther; S Klingberg; M Gastpar; M Riedel
Journal:  Pharmacopsychiatry       Date:  2010-10-06       Impact factor: 5.788

2.  Prodromal symptoms of relapse in schizophrenic outpatients: retrospective and prospective study.

Authors:  Y Henmi
Journal:  Jpn J Psychiatry Neurol       Date:  1993-12

3.  Hospital and community-based care for patients with chronic schizophrenia in Hong Kong--quality of life and its correlates.

Authors:  Grace W L Chan; Gabor S Ungvari; Daniel T L Shek; John J P Leung Dagger
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2003-04       Impact factor: 4.328

4.  Remission and residual symptomatology in major depression.

Authors:  E S Paykel
Journal:  Psychopathology       Date:  1998       Impact factor: 1.944

5.  Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms.

Authors:  Feea R Leifker; Christopher R Bowie; Philip D Harvey
Journal:  Schizophr Res       Date:  2009-09-22       Impact factor: 4.939

6.  Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.

Authors:  Somaia Mohamed; Robert Rosenheck; Joseph McEvoy; Marvin Swartz; Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2008-06-26       Impact factor: 9.306

Review 7.  Schizophrenia, "just the facts" 4. Clinical features and conceptualization.

Authors:  Rajiv Tandon; Henry A Nasrallah; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2009-03-27       Impact factor: 4.939

8.  Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.

Authors:  John M Kane; David T Crandall; Ronald N Marcus; James Eudicone; Andrei Pikalov; William H Carson; Wim Swyzen
Journal:  Schizophr Res       Date:  2007-07-17       Impact factor: 4.939

9.  Sociodemographic and clinical factors associated with relapse in schizophrenia.

Authors:  Gobind Chabungbam; Ajit Avasthi; Pratap Sharan
Journal:  Psychiatry Clin Neurosci       Date:  2007-12       Impact factor: 5.188

Review 10.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

View more
  8 in total

1.  Schizophrenia spectrum and related neuropathology.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03       Impact factor: 5.270

2.  New aspects of the vulnerability stress model in general, its relevance in schizophrenic psychoses and the place of antipsychotics.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-09       Impact factor: 5.270

Review 3.  Pharmacological treatment of negative symptoms in schizophrenia.

Authors:  Hans-Jürgen Möller; Pal Czobor
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-04-21       Impact factor: 5.270

4.  An international multi-site, randomized controlled trial of a mindfulness-based psychoeducation group programme for people with schizophrenia.

Authors:  W T Chien; D Bressington; A Yip; T Karatzias
Journal:  Psychol Med       Date:  2017-04-04       Impact factor: 7.723

5.  Therapy resistance/chronicity, their determinants and potential solutions.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-02       Impact factor: 5.270

Review 6.  Aerobic exercise in severe mental illness: requirements from the perspective of sports medicine.

Authors:  Peter Falkai; Andrea Schmitt; Christian P Rosenbeiger; Isabel Maurus; Lisa Hattenkofer; Alkomiet Hasan; Berend Malchow; Pascale Heim-Ohmayer; Martin Halle; Melanie Heitkamp
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-12-06       Impact factor: 5.760

Review 7.  Dysfunction in the coagulation system and schizophrenia.

Authors:  S Hoirisch-Clapauch; O B Amaral; M A U Mezzasalma; R Panizzutti; A E Nardi
Journal:  Transl Psychiatry       Date:  2016-01-05       Impact factor: 6.222

Review 8.  The Predictive Coding Account of Psychosis.

Authors:  Philipp Sterzer; Rick A Adams; Paul Fletcher; Chris Frith; Stephen M Lawrie; Lars Muckli; Predrag Petrovic; Peter Uhlhaas; Martin Voss; Philip R Corlett
Journal:  Biol Psychiatry       Date:  2018-05-25       Impact factor: 13.382

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.